JP6550333B2 - ペプチドに誘導されたタンパク質ノックダウン - Google Patents

ペプチドに誘導されたタンパク質ノックダウン Download PDF

Info

Publication number
JP6550333B2
JP6550333B2 JP2015533387A JP2015533387A JP6550333B2 JP 6550333 B2 JP6550333 B2 JP 6550333B2 JP 2015533387 A JP2015533387 A JP 2015533387A JP 2015533387 A JP2015533387 A JP 2015533387A JP 6550333 B2 JP6550333 B2 JP 6550333B2
Authority
JP
Japan
Prior art keywords
peptide
protein
cts
dapk1
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015533387A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015533817A (ja
JP2015533817A5 (https=
Inventor
ティアン ワング、ユー
ティアン ワング、ユー
ファン、シュエライ
ヤング ジン、ウー
ヤング ジン、ウー
Original Assignee
ザ ユニヴァーシティ オヴ ブリティッシュ コロンビア
ザ ユニヴァーシティ オヴ ブリティッシュ コロンビア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ユニヴァーシティ オヴ ブリティッシュ コロンビア, ザ ユニヴァーシティ オヴ ブリティッシュ コロンビア filed Critical ザ ユニヴァーシティ オヴ ブリティッシュ コロンビア
Publication of JP2015533817A publication Critical patent/JP2015533817A/ja
Publication of JP2015533817A5 publication Critical patent/JP2015533817A5/ja
Application granted granted Critical
Publication of JP6550333B2 publication Critical patent/JP6550333B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21031—Urokinase (3.4.21.31)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24029—Aureolysin (3.4.24.29)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
JP2015533387A 2012-09-27 2013-09-27 ペプチドに誘導されたタンパク質ノックダウン Expired - Fee Related JP6550333B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261706506P 2012-09-27 2012-09-27
US61/706,506 2012-09-27
PCT/CA2013/050741 WO2014047741A1 (en) 2012-09-27 2013-09-27 Peptide directed protein knockdown

Publications (3)

Publication Number Publication Date
JP2015533817A JP2015533817A (ja) 2015-11-26
JP2015533817A5 JP2015533817A5 (https=) 2016-11-04
JP6550333B2 true JP6550333B2 (ja) 2019-07-24

Family

ID=50386747

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015533387A Expired - Fee Related JP6550333B2 (ja) 2012-09-27 2013-09-27 ペプチドに誘導されたタンパク質ノックダウン

Country Status (7)

Country Link
US (3) US10287333B2 (https=)
EP (1) EP2900697B1 (https=)
JP (1) JP6550333B2 (https=)
CN (2) CN104797603B (https=)
AU (1) AU2013323101C1 (https=)
CA (1) CA2885894C (https=)
WO (1) WO2014047741A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108779167A (zh) * 2015-10-28 2018-11-09 宾夕法尼亚州大学信托人 鞘内施用腺伴随病毒载体用于基因治疗
WO2017079723A1 (en) * 2015-11-07 2017-05-11 Board Of Regents, The University Of Texas System Targeting proteins for degradation
CN116082457A (zh) 2016-02-01 2023-05-09 堪培拉大学 蛋白化合物及其用途
EA037848B1 (ru) * 2016-07-14 2021-05-27 Общество С Ограниченной Ответственностью "Биохимический Агент" Гибридный белок, полинуклеотид, генетическая конструкция, продуцент, препарат для регенерации хряща (варианты)
WO2018103038A1 (zh) * 2016-12-08 2018-06-14 拜西欧斯（北京）生物技术有限公司 一种缀合物及其应用
US10906949B2 (en) * 2017-06-28 2021-02-02 The Cleveland Clinic Foundation Methods of treating spinal cord injury using a chondroitin sulfate proteoglycan (CSPG) reduction peptide (CRP) comprising a cell membrane penetrating domain, a CSPG binding domain, and a lysosome targeting domain
CN109553685B (zh) * 2017-09-25 2021-07-27 华中科技大学 一种小分子多肽及其在制备防治缺血性脑卒中药物中的应用
WO2019090390A1 (en) 2017-11-08 2019-05-16 University Of Canberra Immunogenic compositions and uses therefor
CN108358999A (zh) * 2018-01-17 2018-08-03 南京师范大学 一种雌激素受体靶向肽及其制备和应用
CN112654702B (zh) * 2018-09-07 2025-05-13 阿斯利康(瑞典)有限公司 改进的核酸酶的组合物和方法
CN111363014A (zh) * 2018-12-26 2020-07-03 苏州格兰科医药科技有限公司 用于治疗创伤性脑损伤的多肽及其用途和制备方法
US20220170930A1 (en) * 2019-03-11 2022-06-02 Fudan University Method for screening compound for treating or preventing polyq-related neurodegenerative diseases
CN110013542B (zh) * 2019-03-20 2022-09-20 南通大学 一种预防/治疗突触核蛋白病的药物及多肽类似物
WO2021223026A1 (en) * 2020-05-06 2021-11-11 University Of British Columbia Ezh1/2 knockdown peptides, methods and uses thereof
CN112142856B (zh) * 2020-09-30 2022-05-03 中国人民解放军空军军医大学 一种用于改善脑卒中兴奋性毒性损伤的特异性降解ndrg2靶向肽及其应用
US20260027179A1 (en) * 2021-02-08 2026-01-29 University Of British Columbia Anti-synucleinopathy peptide and methods to treat neurodegenerative diseases
CN115215939B (zh) * 2021-04-14 2025-09-23 中山大学 一种融合蛋白及其制备方法与应用
CN116102657A (zh) * 2021-11-09 2023-05-12 四川大学华西医院 一种基于多肽Pep42构建的嵌合抗原受体免疫细胞制备及其应用
WO2024044493A2 (en) * 2022-08-22 2024-02-29 The Johns Hopkins University Treatment of repeat expansion disease
CN115957348A (zh) * 2023-02-23 2023-04-14 澳门科技大学 靶向类风湿性关节炎脂质体递药系统、制备方法及应用
CN116590342B (zh) * 2023-05-11 2026-04-03 普递瑞(上海)医药有限公司 一种aav载体及其应用
WO2024229777A1 (zh) * 2023-05-11 2024-11-14 深圳先进技术研究院 一种aav载体及其应用
WO2025113706A1 (zh) * 2023-12-01 2025-06-05 苏州格兰科医药科技有限公司 一种化学修饰的多肽
WO2025113713A1 (zh) * 2023-12-01 2025-06-05 苏州格兰科医药科技有限公司 用于治疗新生儿缺氧缺血性脑病的组合物和方法
CN119638819B (zh) * 2024-12-04 2025-12-30 厦门大学 一种靶向降解tmem59多肽及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225444B1 (en) 1998-02-10 2001-05-01 Protarga, Inc. Neuroprotective peptides and uses thereof
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
WO2001047496A1 (en) * 1999-12-29 2001-07-05 Mixson A James Histidine copolymer and methods for using same
US6632616B2 (en) 2000-03-16 2003-10-14 Duke University Compounds that selectively bind to expanded polyglutamine repeat domains and methods of use thereof
JP2003009883A (ja) * 2001-07-05 2003-01-14 Mitsubishi Pharma Corp マスト細胞の細胞死誘発剤
AU2002365396A1 (en) * 2001-11-21 2003-06-10 The Trustees Of The University Of Pennsylvania Peptides, peptide compositions,and methods of use in binding p 185
US7740839B2 (en) * 2003-10-31 2010-06-22 Tae-Yoon Kim EC SOD and cell transducing EC SOD and use thereof
US20060014712A1 (en) * 2004-05-30 2006-01-19 Cemines, Inc. Controlled delivery of therapeutic compounds
CN101374860A (zh) * 2005-12-23 2009-02-25 技术转让合伙人公司 用作神经递质分泌抑制剂和肌肉松弛诱导物的合成肽
US20070244057A1 (en) 2006-01-20 2007-10-18 Henry Paulson Suppressing polyglutamine aggregation and toxicity
US7744879B2 (en) 2006-06-07 2010-06-29 Wisconsin Alumni Research Foundation Blood-brain barrier targeting antibodies
CN101008012A (zh) * 2006-10-27 2007-08-01 王尚武 一种新型人源神经营养因子bdnf表达结构及其表达
CN101134780A (zh) * 2007-07-09 2008-03-05 南京医科大学 阻断nr2b信号通路的多肽类似物及其制备方法和药物用途
US20100016221A1 (en) 2008-07-17 2010-01-21 Riken Method of degrading protein by chaperone-mediated autophagy
HRP20160385T1 (hr) * 2009-03-09 2016-05-06 Ramot At Tel-Aviv University Ltd. Pripravci za prevenciju i liječenje neurodegenerativnih bolesti
US9746475B2 (en) * 2011-03-14 2017-08-29 University Of Southern California Antibody and antibody mimetic for visualization and ablation of endogenous proteins
US20130065267A1 (en) * 2011-09-09 2013-03-14 Emory University Conjugates and methods for measuring chaperone-mediated autophagy

Also Published As

Publication number Publication date
US12428456B2 (en) 2025-09-30
AU2013323101C1 (en) 2021-08-19
CN104797603A (zh) 2015-07-22
WO2014047741A1 (en) 2014-04-03
CN104797603B (zh) 2020-11-10
US10287333B2 (en) 2019-05-14
CN112225819A (zh) 2021-01-15
EP2900697A4 (en) 2016-04-20
AU2013323101A1 (en) 2015-04-23
EP2900697A1 (en) 2015-08-05
US20150266935A1 (en) 2015-09-24
JP2015533817A (ja) 2015-11-26
US11186620B2 (en) 2021-11-30
US20220056088A1 (en) 2022-02-24
EP2900697B1 (en) 2020-08-05
AU2013323101B2 (en) 2018-07-12
CA2885894C (en) 2021-11-23
US20190315819A1 (en) 2019-10-17
CA2885894A1 (en) 2014-04-03

Similar Documents

Publication Publication Date Title
US12428456B2 (en) Peptide directed protein knockdown
CN102015758B (zh) 寡肽化合物及其应用
US20160074472A1 (en) Inhibitors of Phosphatase and Tensin Homolog (PTEN) Compositions, Uses and Methods
CA2878701C (en) Neuroprotective pepties that inhbit interaction between palmitoyl acyl transferase zinc-finger dhhc type containing 17 (zd17) and c-jun n-terminal kinase (jnk)
US20180327458A1 (en) Pharmaceutical compositions for prevention or treatment of neurodegenerative diseases
CA2996951C (en) Peptide inhibitors of telomerase translocation and therapeutic uses thereof
US9593148B2 (en) DPP8 and DPP9 peptide inhibitors
KR101131512B1 (ko) 퇴행성신경질환 예방 또는 치료용 약제학적 조성물
WO2007109908A1 (en) Therapeutic yb-1 phosphorylation decoys
AU2017214761A1 (en) Proteinaceous compounds and uses therefor
Nougarede Molecular basis of BCL2L10/Nrh oncogenic activity in breast cancer
Duong et al. Cell-Permeable Parkin Proteins Suppress Parkinson Disease-Associated Phenotypes in Cultured Cells and
IL194466A (en) Variants of the V-N terminal of VDAC and their use

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20150722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160914

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160914

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170801

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171025

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180202

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190121

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190520

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190604

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190701

R150 Certificate of patent or registration of utility model

Ref document number: 6550333

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees